Tenaya Therapeutics, Inc. (TNYA)

Market Cap	175.87M
Revenue (ttm)	n/a
Net Income (ttm)	-117.23M
Shares Out	79.22M
EPS (ttm)	-1.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,667,574
Open	2.450
Previous Close	2.270
Day's Range	2.175 - 2.450
52-Week Range	1.610 - 7.010
Beta	2.35
Analysts	Strong Buy
Price Target	14.75 (+564.41%)
Earnings Date	Nov 6, 2024

About TNYA

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arr...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 140
• Stock Exchange: NASDAQ
• Ticker Symbol: TNYA
• Website: https://www.tenayatherapeutics.com

Analyst Forecast

According to 5 analysts, the average rating for TNYA stock is "Strong Buy." The 12-month stock price forecast is $14.75, which is an increase of 564.41% from the latest price.

Price Target

$14.75

(564.41% upside)

Analyst Consensus: Strong Buy